POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST

NCT03171389 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

81

Enrollment

OTHER

Sponsor class

Conditions

GIST, Malignant
KIT Exon 13 Mutation
KIT Gene Mutation

Interventions

DRUG: Ponatinib 30 MG

Sponsor

Sebastian Bauer

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]